A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer
Advanced Science · 2026
DOI: 10.1002/advs.75933 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Advanced Science, 2026. Verfasst von Yanglan Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immunotherapy, Lung Neoplasms, Neoadjuvant Therapy. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Excellent Young Talents Project of Shanghai Public Health Three-year (2023-2025) Action Plan.
Abstract (Originalsprache)
Predicting pathological complete response (pCR) to neoadjuvant immunochemotherapy in non‐small cell lung cancer (NSCLC) is clinically important yet remains challenging. Here, we introduce a foundation model‐derived computed tomography (CT) imaging biomarker established from a multi‐center cohort of 702 patients. Specifically, we developed and validated a non‐invasive baseline CT‐based model for risk stratification of pathological response. To address scanner and protocol heterogeneity, we first built a 3D Vision Mamba‐based CT super‐resolution model trained on 2494 cases for image standardization. We then fine‐tuned a lung cancer‐specific CT foundation model from a pretrained 3D model (VoCo) using 6643 chest CT scans. Finally, we constructed a multi‐task Swin Transformer that jointly performs risk stratification and segments tumors to generate the imaging biomarker. Across five centers, the model achieved consistently strong generalization (AUC: 0.75–0.87) for pCR prediction. Genomic analysis revealed that the biomarker was independent of tumor mutational burden but significantly associated with TP53 mutations, suggesting an association with a radiogenomic phenotype related to this alteration. Together, these results demonstrate a generalizable and biologically meaningful foundation model‐based biomarker for non‐invasive risk stratification of pathological response in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Radiology, Shanghai Pulmonary Hospital, Shanghai, China.
- Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Shanghai Institute of Medical Imaging, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
- Excellent Young Talents Project of Shanghai Public Health Three-year (2023-2025) Action Plan
- Science Foundation of Peking University Cancer Hospital
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Xu, Y., Zhou, S., Peng, Q., Bao, X., Ye, X., Er, A. G., Tong, T., Rusu, M., Gu, Y., Chen, M., & Gong, J. (2026). A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer. Advanced Science. https://doi.org/10.1002/advs.75933
Vancouver
Xu Y, Zhou S, Peng Q, Bao X, Ye X, Er AG, et al. A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer. Advanced Science. 2026. doi:10.1002/advs.75933
BibTeX
@article{Xu2026,
author = {Xu, Yanglan and Zhou, Shuchang and Peng, Qin and Bao, Xiao and Ye, Xiaodan and Er, Ahmet Görkem and Tong, Tong and Rusu, Mirabela and Gu, Yajia and Chen, Mailin and Gong, Jing},
title = {A Foundation Model Based CT Biomarker for Non‐Invasive Prediction of Response to Neoadjuvant Immunochemotherapy in Non‐Small Cell Lung Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.75933}
}
EUVIMED